Blaze Bioscience Lands $9,000,000 Series B Round

  • Feed Type
  • Date
    12/3/2013
  • Company Name
    Blaze Bioscience
  • Mailing Address
    530 Fairview Avenue North Seattle, WA 98109
  • Company Description
    Blaze Bioscience was founded in 2010 to develop and commercialize Tumor Paint technology, which has the potential to fundamentally transform surgical oncology.
  • Website
    http://www.blazebioscience.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $9,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will be used to support the clinical development of Blaze’s first Tumor PaintTM product candidate, BLZ-100, which is designed to assist surgeons in surgical excision of solid tumors by illuminating cancer cells intra-operatively in real time and at high resolution. A Phase 1 clinical trial of BLZ-100 will be initiated shortly. In addition, the company will use proceeds to support development of Optide drug candidates as part of the collaboration and option agreement entered into with Fred Hutchinson Cancer Research Center in June of this year.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy